Pfizer will sell its remaining stake in British consumer healthcare group Haleon , the companies said on Tuesday.

Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for ...

Haleon has gained full control of its Chinese joint venture after acquiring Tianjin Pharmaceutical Da Ren Tang's 12% stake.

Pfizer PFE has sold off its remaining stake in consumer health company Haleon HLN to institutional investors and Haleon itself for around $3.3 billion. Pfizer sold its 7.3% stake in Haleon ...

(Bloomberg) -- Pfizer Inc. raised about £2.55 billion ($3.3 billion) through the sale of its remaining 7.3% stake in Haleon Plc, culminating a years-long separation from the maker of Sensodyne ...

Pfizer has completing its full exit from Weybridge-headquartered health firm Haleon. Haleon has agreed to an off-market purchase of 44,155,844 ordinary shares of £0.01 each from Pfizer. The off-market ...

US pharmaceutical firm Pfizer (PFE) has sold off its remaining stake in Sensodyne and Panadol maker Haleon (HLN.L) for around £2.5 billion. Haleon has agreed to buy back 44 million shares from Pfizer ...

Haleon was formed in 2019 by the merger of the consumer healthcare businesses of British pharmaceutical group GSK and US rival Pfizer. Haleon floated on the London Stock Exchange with a value of ...

Pfizer sold its remaining 7.3% stake in Haleon for $3.1 billion, fully exiting its position in the company. Haleon expects 2025 organic revenue growth of 4% to 6%, with stronger performance in the ...